Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (541)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis

  3. Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] (Autoimmunity Reviews (2023) 22(12), (S1568997223002136), (10.1016/j.autrev.2023.103479))

    Autoimmunity Reviews

  4. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259

  5. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  6. Health service and psychotropic medication use for mental health conditions among healthcare workers active during the Spain Covid-19 Pandemic – A prospective cohort study using web-based surveys.

    Psychiatry Research, Vol. 334

  7. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

  8. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

    RMD open, Vol. 10, Núm. 1

  9. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

  10. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  11. PRPH2-Related Retinal Dystrophies: Mutational Spectrum in 103 Families from a Spanish Cohort

    International Journal of Molecular Sciences, Vol. 25, Núm. 5

  12. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease

  13. Presurgical invasive mediastinal staging in lung cancer, unexpected N2 and long-term survival: a registry-based study with data from the Spanish group for video-assisted thoracic surgery

    Journal of Thoracic Disease, Vol. 16, Núm. 5, pp. 2856-2865

  14. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

  15. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

  16. Pulmonary Embolism

    Open Respiratory Archives, Vol. 6, Núm. 4

  17. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 95, Núm. 5, pp. 410-418

  18. Somatic CAG repeat instability in intermediate alleles of the HTT gene and its potential association with a clinical phenotype

    European Journal of Human Genetics

  19. Surgery for inflammatory bowel disease in Spain: How are we doing? Initial results of a nationwide prospective registry

    Cirugia Espanola

  20. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789